0058 GMT - Monash IVF keeps its bull at Wilsons despite its guidance downgrade. Analyst Shane Storey thinks that the downgrade, which left the company's FY25 underlying profit guidance 9% below the average analyst forecast, is primarily due to softer cycle volumes across the industry. He points out in a note to clients that Monash still managed to maintain market share in the March quarter, which gives him some comfort on its prospects. He is conservative in his forecasts for cycle growth but still thinks that there is considerable upside to the stock at current levels. Wilsons cuts its target price 11% to A$1.25 and stays overweight on the stock, which is down 0.6% at A$0.775. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

May 26, 2025 20:58 ET (00:58 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.